The US Senate approved a measure (HR 2642) that would provide the US Food and Drug Administration with $275 million in additional funding under a supplemental appropriations bill. The measure now goes before the House.
Washington, DC (May 22)-The US Senate approved a measure (HR 2642) that would provide the US Food and Drug Administration with $275 million in additional funding under a supplemental appropriations bill. The measure now goes before the House.
Earlier this month, FDA Commissioner Andrew von Eschenbach outlined in a letter to Arlen Specter, ranking member of the Senate Subcommittee on Labor, Health and Human Services, Education and Regulated Agencies, the agency's immediate needs as part of discussions for a supplemental budget request. The $275-million request included $100 million for drug, medical device, and biologics safety, $125 million for food protection, and $50 million for modernizing FDA’s science and workforce.
FDA’s request for an additional $100 million in drug-safety funding would allow for 120 more foreign inspections and 575 more domestic inspections. It would also support additional measures for risk-based inspection and compliance. These measures include improvements to laboratory infrastructure for rapid analysis of product and ingredient content, increasing import exams and sample/laboratory analysis, improvements in IT infrastructure, and allowing FDA to expand globally.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.